Details for: INVEGA TRINZA
Company: JANSSEN INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02455943 | INVEGA TRINZA | PALIPERIDONE (PALIPERIDONE PALMITATE) | 175 MG / 0.875 ML | SUSPENSION (EXTENDED-RELEASE) | INTRAMUSCULAR |
| 02455986 | INVEGA TRINZA | PALIPERIDONE (PALIPERIDONE PALMITATE) | 263 MG / 1.315 ML | SUSPENSION (EXTENDED-RELEASE) | INTRAMUSCULAR |
| 02455994 | INVEGA TRINZA | PALIPERIDONE (PALIPERIDONE PALMITATE) | 350 MG / 1.75 ML | SUSPENSION (EXTENDED-RELEASE) | INTRAMUSCULAR |
| 02456001 | INVEGA TRINZA | PALIPERIDONE (PALIPERIDONE PALMITATE) | 525 MG / 2.625 ML | SUSPENSION (EXTENDED-RELEASE) | INTRAMUSCULAR |
Summary Reports
Regulatory Decision Summary
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.